Revenio Q2 2026 slides: Visionix lifts sales, margins sink

Revenio's Q2 2026 sales rose 48.1% to EUR 39.3 million following one month of Visionix consolidation, but legacy organic sales were flat and adjusted EBIT margin fell 10.1 percentage points year over year to 14.6%. Reported EBIT declined 60.9% to EUR 2.4 million, gross margin dropped to 64.7% from 72.6%, and operating cash flow turned negative EUR 2.4 million. Net debt reached EUR 237.9 million, or 5.3x adjusted EBITDA, prompting a planned EUR 80 million rights issue; shares fell 18.28% in pre-market trading. Management targets more than EUR 20 million of EBITDA synergies by 2029 and guided 2026 currency-adjusted sales to EUR 190-205 million.

Analysis

REG1V has shifted from a premium-margin medtech compounder to a leveraged integration execution story. The key valuation risk is not the acquisition charge itself, but whether lower hardware mix, tariffs and component inflation permanently reset consolidated margins below the historical range; a 3-5 percentage-point miss versus the long-term margin target would materially impair deleveraging capacity and justify a lower EV/EBITDA multiple. Near-term earnings quality is also weak because working-capital absorption and integration cash costs make reported EBITDA a poor proxy for debt paydown.

The rights issue creates a likely technical overhang through pricing and completion in mid/late H2, particularly after a sharp share decline. Anchor commitments reduce deal-break risk but do not eliminate dilution or a discount-driven reset; the relevant question is whether post-raise leverage falls sufficiently to restore strategic flexibility before lenders or suppliers demand tighter terms. NDA.FI has modest fee/underwriting exposure rather than meaningful earnings sensitivity, while DEMANT is the more relevant read-through: disruption at a smaller ophthalmic/optical competitor could create channel openings, but only if REG1V preserves product availability and sales-force retention.

The September 15 CMD is the immediate catalyst. A credible bridge from current profitability to the medium-term target—separating procurement savings, tariff mitigation, revenue synergies, integration costs and capex—could support a tactical bounce, but vague targets would reinforce the view that the acquisition was underwritten on optimistic synergies. Contrarian upside exists if tariff pressure normalizes and cross-selling converts faster than expected, since the selloff may already price substantial execution failure; confirmation requires improving organic orders and operating cash conversion, not another run-rate synergy claim.

Over 6-18 months, the most important KPI is cash conversion after restructuring, alongside net debt/EBITDA progress toward roughly 3x. Failure to show positive operating cash flow and sequential gross-margin stabilization by the next two reporting periods would make further equity dilution, covenant pressure, or asset rationalization increasingly plausible.

Key Decisions for Investors

• Avoid initiating a core long in REG1V before the rights-issue terms and September 15 CMD. Reassess only if management provides a quantified margin bridge and the equity raise clears at a limited discount; a post-deal 3x leverage path with positive cash flow is the minimum condition.
• Tactical short/watch: sell REG1V rallies following the CMD if management does not quantify tariff mitigation, cross-sell KPIs and 2027 cash conversion. Cover if gross margin stabilizes sequentially and management demonstrates organic order acceleration; position sizing should reflect potentially high borrow and rights-related volatility.
• For existing REG1V holders, participate in the rights offering only after confirming subscription price, underwriting structure and pro-forma covenant headroom. The relevant downside trigger is another material reduction in profitability expectations or evidence that working capital remains a cash drain after integration payments roll off.
• Use DEMANT as a relative hedge rather than a direct sympathy trade: long DEMANT versus short REG1V can express better balance-sheet quality and execution certainty in optical/diagnostics over 3-6 months. Exit the pair if REG1V reports measurable cross-selling traction and margin recovery while DEMANT’s growth decelerates.